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Objective: Our objective was to explore whether adults hold different beliefs about   medications 
to which they persist vs nonpersist and persist vs nonfulfull.
Methods: We conducted a cross-sectional survey of adults with asthma, hypertension,   diabetes, 
hyperlipidemia, osteoporosis, or other cardiovascular disease from the Harris Interactive Chronic 
Illness Panel. A quota was set to obtain a sample of respondents who were persistent to a   medication 
for one disease and nonpersistent or nonfulfilling to a medication for a second,   different disease. 
Respondents completed 32 items yielding five multi-item scales: perceived need for medication 
(k = 12), side-effect concerns (k = 5), medication-safety concerns (k = 5), perceived disease sever-
ity (k = 3), and knowledge about the prescribed medication (k = 7). Respondents completed the 
32 items twice – once for their persistent medication and a second time for their nonpersistent or 
nonfulfilling medication. Paired sample t-tests (bivariate) and generalized   estimating equations 
(GEE) models (multivariate) were used to test the study hypotheses.
Results: Overall, 178 respondents were sampled for being persistent to one medication and 
nonpersistent to another, while 48 respondents were persistent to one medication and nonfulfilling 
to a second. For the medication to which an individual patient was persistent vs nonpersistent, 
there was significantly higher perceived need, fewer side-effect concerns, higher perceived 
disease severity, and better knowledge about the medication. For the medication to which an 
individual patient was persistent vs nonfulfilling, there was significantly higher perceived need, 
fewer side-effect concerns, and better knowledge about the medication.
Conclusion: Individual patients hold different beliefs about medications to which they persist 
vs nonpersist or nonfulfill. Patients exhibit different medication-taking behaviors for different 
medications because they weigh the perceived risks and benefits for each medication separately. 
These results suggest that adherence interventions should be tailored to patients’ beliefs about 
specific medications.
Keywords: adherence, persistence with therapy, medication beliefs, chronic disease, primary 
nonadherence, medication nonfulfilment
Introduction
Prescription medications are an essential pillar of primary and specialty care with 
70% of ambulatory visits involving a provided, prescribed, or continued medication.1 
  Nonadherence to prescription medications is a problem of international importance 
that knows no demographic, geographic, or political boundaries. A recent   systematic 
review reported that, across 79 studies, approximately 16% of patients fail to fill a new 
  prescription (otherwise known as primary nonadherence or medication nonfulfillment).2 
  Approximately one half of patients who fill a new prescription stop taking their   medication 
in the first year of therapy (otherwise known as medication nonpersistence).3Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Three key adherence ‘myth busters’ have emerged from 
five decades of adherence research. First, there are very 
weak associations between sociodemographic   characteristics 
and adherence.4,5 In a seminal meta-analysis, DiMatteo5 
found the average correlation between adherence and age 
and gender to be zero and the average correlation between 
adherence and education and income to be less than 0.10. 
Second, across6 and within6–10 chronic diseases, there is 
weak   correspondence between medication adherence and 
  adherence to lifestyle and self-care recommendations. 
Third, many researchers have dismissed the plausibility of 
an ‘adherent personality.’11–14 Hevey14 asserts that ‘there is 
little evidence of personality traits influencing adherence 
and the search for the “  nonadherent” personality type has 
provided limited insight.’ These three findings have gone far 
towards redirecting research away from trait characteristics 
and toward patients’ mutable characteristics, ie, their beliefs 
about their treatment and their disease.
Conceptual work has described adherence as a reasoned 
decision15,16 and has explained how patients differentially 
value   different medications.16,17 Qualitative research has shed 
light on how medication taking is a decision-making process 
and has illustrated how patients balance their concerns about 
medications against their perceived need for the therapy 
and its perceived benefits.13,15,18–24 Quantitative research has 
  documented that patient beliefs about their treatment, condi-
tion, and prognosis, as well as their objective experiences with 
their treatment, differentiate adherers from nonadherers.25–38
If adherence is not a trait characteristic, it stands to reason 
that individual patients should exhibit different adherence 
patterns to different medications because they make deci-
sions for each medication according to their beliefs as well 
as to the information they possess about the medication and 
the condition. Thus, adherence should represent shades of 
grey – individual patients can be persistent to some medica-
tions, nonpersistent to others, and fail to fill others because 
they make separate decisions about each medication. Research 
has indeed demonstrated that individual patients have   distinct 
adherence patterns to assorted medications.30,39–53 For example, 
Chapman41,49 reported differential persistence to concomitant 
antihypertensive and lipid-lowering therapy, and Piette48 
found differential persistence to antihyperglycemic, anti-
hypertensive, and antipsychotic medications. Research has 
also shown that individual patients attach differential worth 
and value to different medications13,34,54 and have diverse 
beliefs for different medications in regard to their perceived 
importance, effectiveness, safety, and expected benefits.13,55,56 
For example, Aikens and Piette56 demonstrated that patients 
prescribed both   antihyperglycemic and   antihypertensive 
medications rated the former as more   necessary to them; the 
  antihyperglycemic   medications also induced more   medication 
concerns than did the   antihypertensive   medications. Finally, 
quantitative research has shown that patients with d  ifferent 
adherence behaviors have different beliefs about their medica-
tions and conditions.30,36,38,57,58 In one study, there was a strik-
ing distinction between self-reported medication persisters 
and nonpersisters on 14 different proximal and intermediate 
adherence drivers.38
Despite the totality of this research, we know of no   published 
studies that show different belief structures within individual 
patients who exhibit different medication-taking behaviors for 
different medications for different chronic   diseases. Herein we 
report a small study of: (1) 178 patients who reported being 
persistent to one medication for one chronic disease and 
  nonpersistent to a different medication for a second chronic 
disease; and (2) 48 patients who reported being   persistent to 
one medication for one chronic disease and not filling a different 
medication for a second chronic disease.
Methods
study design
sampling procedure
As described in detail elsewhere,38 survey participants were 
selected from the Harris Interactive Chronic Illness Panel 
(CIP), a nationally-representative, Internet-based panel 
of hundreds of thousands of adults with chronic disease. 
Respondents were eligible for the survey if they were aged 
40 and older, resided in the U.S., and reported having at least 
one of six chronic diseases prevalent among U.S. adults: 
asthma, diabetes, hyperlipidemia, hypertension, osteoporosis, 
or other cardiovascular disease. Panel members responding to 
an email invitation were instructed to read the informed con-
sent form and click on yes if they agreed to participate. The 
protocol for the survey was approved by the Essex IRB.
Three groups of respondents were identified based on 
their medication-taking behavior: self-reported persisters, 
self-reported nonpersisters, and self-reported nonfulfillers 
to prescription medications. Of the 1,283 respondents to 
the survey, 1,072 were sampled for a single medication-
taking behavior while 226 were sampled for more than one 
medication-taking behavior (ie, persistent to a medication for 
one disease and nonpersistent to a medication for a different 
disease [n = 178]; persistent to a medication for one disease 
and nonfulfilling to a medication for a different disease 
[n = 48]). These latter sample members (n = 226) are used 
in the analyses reported herein.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Definition of medication persisters,  
nonpersisters, and nonfulfillers
During the screening portion of the survey, panel members’ 
chronic disease status was reconfirmed. The screener   solicited 
the number of medications respondents currently took for 
each disease as well as the length of time they reported they 
had been continuously taking the medication. These items 
were used to classify respondents as currently persistent to 
their medication. To identify respondents as nonpersisters, 
the survey asked if, in the last year, they had stopped taking a 
prescription medication for one of the six conditions without 
their providers telling them to do so. To identify respondents 
as nonfulfillers, the survey asked if, in the last year, they 
had received, but did not fill, a new prescription from their 
provider for one of the six target conditions.
survey content
The  226  respondents  sampled  for  more  than  one 
  medication-taking behavior completed a core set of   questions 
on demographics (including age, gender, education, income, 
and race) and self-reported health. The 226 respondents 
also completed two identical sets of 32 questions assessing 
perceived need for medication (k = 12), side-effect concerns 
(k = 5),   medication-safety concerns (k = 5), perceived dis-
ease severity (k = 3), and knowledge about the prescribed 
medication (k = 7).   Respondents   completed each of the 32 
items twice: once for each of the two medications for which 
they self-reported different medication-taking behaviors. As 
described in detail elsewhere,38 multi-item scales were created 
by summing raw items into a scale score and linearly trans-
forming each sum to a 0–100 metric, with 100 representing 
the most favorable belief (highest perceived need, fewest 
side-effect concerns, fewest medication-safety concerns, 
highest perceived   disease   severity, and best knowledge), 0 
the least favorable, and scores in between representing the 
percentage of the total possible score.38 The multi-item scales 
were internally consistent, with Cronbach’s alpha coefficients 
ranging from 0.76–0.96 (median of 0.87).38
statistical analysis
It was hypothesized that respondents would express 
  statistically-different beliefs about the different medica-
tions to which they showed (1) persistence vs nonpersis-
tence and (2) persistence vs nonfulfillment. Paired sample 
t-tests and generalized estimating equations (GEE) models 
were used to determine whether patients’ scores were 
significantly   different for the different medication-taking 
behaviors.
Most standard multivariate techniques assume that 
  observations used in an analysis are independent of all   others. 
This assumption is violated if repeated observations are taken 
within subjects, such as in this study, because such   observations 
tend to be correlated with each other. When faced with such 
data, researchers must account for the correlation within 
responses when estimating regression parameters.59 Failure 
to incorporate correlation of responses can lead to incorrect 
estimation of model parameter estimates; in particular, the 
standard error can be too small, increasing the likelihood that 
a parameter is statistically significant when it truly is not.
Generalized estimating equations (GEE)60,61 are employed 
as a means of testing hypotheses regarding the influence of 
factors on response variables collected within subjects across 
time. The GEE models in this study were estimated specifying 
a Gaussian distribution of the   dependent variable, an identity 
link function, and an exchangeable   correlation matrix with 
robust standard errors. The principal independent variable in 
the GEE models was a dichotomous indicator of whether a 
person’s response for a specific scale was for a medication 
for which they were persistent or not (either nonpersistent or 
nonfulfiller). Covariates included patient-level demograph-
ics (age, gender, race, education, income, and self-reported 
health) as well as dummy variables for the diseases groups.
Results
Persistent vs nonpersistent
Table 1 shows the demographic characteristics of the 
  persistent versus nonpersistent sample. Two-thirds of 
respondents were female and had a mean age of 60 years. 
A majority of the respondents were white (90%), had better 
than a high-school education (79%), and reported their health 
as being fair or poor (63%).
Table 2 reports the results of paired t-tests. For four 
of the five scales, the mean scores for the nonpersistent 
  medication were significantly lower than those for the 
  persistent   medication. Side-effect concerns showed the 
largest   difference between persistent and nonpersistent 
medications (15.6% lower for nonpersistent medication), 
followed by perceived need for medications (14.5% lower for 
nonpersistent medication), perceived disease severity (9.2% 
lower for nonpersistent medication), and knowledge (3.6% 
lower for nonpersistent medication).
Table 3 shows results of the GEE models. After   controlling 
for several covariates, respondents had significantly lower 
perceived need, more side-effect concerns, lower perceived 
disease severity, and less knowledge for the medication to 
which they were nonpersistent vs persistent.Patient Preference and Adherence 2010:4
Table 1 Demographic characteristics
Variable Persistent  
versus 
nonpersistent 
N = 178
Persistent 
versus 
nonfulfillment 
N = 48
N % N %
Age, mean (SD)  59.8  10.8 63.4  10.8
40–49 37  20.8% 4    8.3%
50–59 48  27.0% 13  27.1%
60–69 62  34.8% 20  41.7%
70–79 24 13.5% 8  16.7%
80+ 7    3.9% 3    6.3%
Gender 
Male 61  34.8% 18  37.5%
Female 117  65.7% 30  62.5%
Education 
High school or less 38  21.4% 8  16.7%
some college 74  41.6% 26  54.2%
college degree 23 12.9% 5  10.4%
Greater than college degree 43 24.2% 9 18.8%
Income
,25K 39  24.7% 8  19.1%
$25K ,50K 46  29.1% 14  33.3%
$50K ,75K 30  19.0% 7  16.7%
$75K ,100K 21  13.3% 8  19.1%
$100K 22  13.9% 5  11.9%
Race 
White 158  89.8% 46  95.8%
Black 5    2.8% 1    2.1%
Hispanic 4    2.3% 0      0%
Other 9    5.1% 1    2.1%
Health 
Fair/poor 111  62.7% 23  47.9%
Good  50  28.1% 21  43.8%
Very good/excellent 17    9.6% 4    8.3%
Medicationa
Hypertension medication 29 16.3% 14 29.2%
Asthma medication 85 47.8% 17 35.4%
Diabetes medication 83 46.6% 13 27.1%
Lipid medication 56 31.5% 18 37.5%
Osteoporosis 
medication
57 32.0% 14 29.2%
Other cVD medication 46 25.8% 20 41.7%
Notes: aThe n’s sum up to twice the number of subjects and the percents sum up 
to 200% because each subject was sampled for their medication-taking behavior on 
two separate medications in two different therapeutic areas.
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Persistent vs nonfulfillment
Table 1 shows the demographic characteristics of the 
  persistent versus nonfulfillment sample. Two-thirds of the 
sampled respondents were female with a mean age of 63 years 
and a majority were white (96%). Almost equal   numbers of 
respondents reported their health as being fair/poor (48%) 
and good (44%).
Table 2 reports the results of paired sample t-tests. Across 
three of the five scales (perceived need for medications, 
side-effect concerns, and knowledge), the mean score for 
the nonfulfilled medication was significantly lower than 
that for the persistent medication. Side-effect concerns scale 
showed the largest difference between scores for persistent 
and nonfulfilled medications (20.2% lower for nonfulfilled 
medication), followed by perceived need for medications 
(17.9% lower for nonfulfilled medication), and knowledge 
(6.3% lower for nonfulfilled medication).
Table 3 shows results of the GEE models. After control-
ling for several covariates, respondents had significantly less 
perceived need for medications, more side-effect concerns, 
and less knowledge for the medication which was not filled 
compared to the persistent medication.
Discussion
Interpretation of study findings
Of the five studied multi-item scales, perceived need for 
medications and medication concerns best differentiated 
between individuals who persisted to one medication and 
stopped taking another, as well as persons who persisted to 
one medication and failed to fill another. These findings are 
consistent with past research which has demonstrated that 
perceived need for medications and medication concerns, 
variously operationalized, predict medication adherence.25–38 
Patients’ beliefs should be modifiable: negative beliefs – such 
as medication concerns – could be assuaged, and positive 
beliefs – such as perceived need for medications – could be 
reinforced through appropriate information and counseling. 
Recent research has demonstrated that patients’ medication 
beliefs can be altered through intervention.62–64
Perceived disease severity is a key component of the 
health belief model65 – an organizing framework that has 
been frequently applied in adherence research. Perceived 
disease severity significantly differentiated persons persis-
tent and nonpersistent to different medications for different 
diseases but not so for persistent vs nonfulfillment. Some 
primary research studies45,66,67 and one meta-analysis68 
found perceived disease severity to be related to medica-
tion nonpersistence, while other primary research studies 
have not.69–73 We are aware of only one study that related 
perceived disease severity to medication nonfulfillment, 
and no significant relationship was found.74 We hypothesize 
that perceived disease severity was a weaker differentiator 
of different medication-taking behaviors within individu-
als because it may influence medication decision-making 
through its direct effect on perceived need for medications 
and medications concerns,38 which is consistent with tenets 
of the health belief model.75Patient Preference and Adherence 2010:4
Table 2 results of paired sample t-tests
Persistent versus nonpersistent medications (N = 178)
Multi-item scale Persistent  
medication
Nonpersistent  
medication
(Persistent) – (Nonpersistent)
Mean Mean Difference (% lower) t-score P-value
Perceived need for medications 77.4 66.2 11.2 (14.5%) 6.7  ,0.001
side-effect concerns 68.5 57.8 10.7 (15.6%) 6.1 ,0.001
Medication-safety concerns 52.2 51.6   0.6 (1.2%) 0.5    0.64
Perceived disease severity 65.3 59.3   6.0 (9.2%) 3.1  ,0.01
Knowledge about the prescribed medication 83.1 80.1   3.0 (3.6%) 3.0 ,0.01
Persistent versus nonfulfilled medications (N = 48)
Multi-item scale Persistent  
medication
Nonfulfilled 
medication
(Persistent) – (Nonfulfilled)
Mean Mean Difference (% lower) t-score P-value
Perceived need for medications 79.8 65.5 14.3 (17.9%)   3.9 ,0.001
side-effect concerns 71.3 56.9 14.4 (20.2%)   3.9 ,0.001
Medication-safety concerns 53.6 53.8 -0.2 (-0.4%) -0.1    0.95
Perceived disease severity 63.7 59.4   4.3 (6.8%)   1.3     0.21
Knowledge about the prescribed medication 87.9 82.4   5.5 (6.3%)   2.9 ,0.01
Table 3 GEE models predicting subjects’ score on the five multi-item scales
Multi-item scale Persistent versus nonpersistent  
medicationsa (N = 338)b
Persistent versus nonfulfilled  
medicationsa (N = 90)b
Coefficient on the  
GEE modelc
P-value Coefficient on the  
GEE modelc
P-value
Perceived need for medications -10.9 ,0.001 -13.0    0.01
side-effect concerns -10.7 ,0.001 -14.3 ,0.001
Medication-safety concerns   0.3    0.85   2.0    0.59
Perceived disease severity  - 6.1 ,0.01  - 2.3    0.68
Knowledge about the  
prescribed medication
 - 2.5    0.02  - 5.9    0.01
Notes: areference category: Persistent medication; beach subject is included twice in the Gee models, once for the persistent medication and once for their nonpersistent/
nonfulfilled medication; ccovariates in the Gee models included: age, gender, education, income, race, self-reported health, and index medication therapeutic area.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
191
Different beliefs to different medication-taking behaviors
Medication-related information is a necessary, but 
not sufficient, condition for effective medication-taking 
behavior.76 Knowledge about the prescribed medication sig-
nificantly differentiated both nonfulfillers and nonpersisters 
from persisters. This finding is consistent with past research 
which has demonstrated that patients desire information 
about their conditions,77 are unaware of the possible clinical 
sequelae of untreated/uncontrolled chronic disease,78 and 
report significant unmet needs for information about the risks 
and benefits of their medications.22,23,77,79–81 While statistically 
significant, knowledge was not as strong a differentiator of 
different medication-taking behaviors as perceived need, 
side-effect concerns, or disease severity. Knowledge has been 
hypothesized to indirectly affect medication-taking behav-
iors through behavioral skills (eg, objective and perceived 
medication-taking skills as well as adherence self-efficacy),82 
personal motivation,76 and health beliefs (general as well 
as medication- and disease-specific).38,83 Thus, the smaller 
effects observed for knowledge in this study may be due 
to its mediating, rather than direct effect, on   medication 
  decision-making. Consistent with this interpretation, a recent 
meta-analysis showed rather small effect sizes for   information 
and educational adherence intervention,84 a finding similar 
to other meta-analyses.85,86
The multi-item scale assessing long-term medication 
safety-concerns was not statistically significant in the 
  bivariate or multivariate analyses. The five items included 
in the scale measured long-term concerns (eg, worry about 
building up a tolerance, worry my body will become depen-
dent on the medication). Given the long-term and future focus 
of the items, it is intuitive that they would have less impact 
on contemporaneous medication decision-making.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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Limitations of the study
Our study is not without limitations. Information on 
  medication-taking behaviors was collected by self report 
and was not corroborated using external indicators, such 
as   pharmacy claims, refill records, pill counts, or electronic 
  monitoring. However, every direct and indirect method of 
  assessing adherence has its limitations, and none are mea-
sured without error. Past research has demonstrated that 
patients reliably report nonadherence.87–89 Thus, we have 
greater confidence in the classification of   nonpersisters 
and nonfulfillers than the self-reported persisters. Any 
  misclassification of the self-reported persisters would have 
served to provide lower-bound estimates of the observed 
findings. We did not sample persons who were persistent to 
prescription medications for two or more different diseases 
or who were persistent to two or more medications for the 
same chronic disease. A natural extension of the results 
reported herein would be to test whether persons persistent 
to multiple medications have equivalent beliefs about those 
medications.
The study involved adults with self-identified chronic 
disease, and none of the six study conditions were substanti-
ated with medical records. However, a well-defined, chronic 
disease panel was accessed and the six conditions were reveri-
fied using a separate, independent screener than that used to 
enroll the CIP. Only six conditions were studied, although 
they are highly prevalent in the U.S. adult population. No 
psychiatric conditions were studied. It is possible that our 
results may vary for certain subgroups of patients, such as 
those based on race/ethnicity. We did not have sufficient 
sample size within the different ethnic groups to conduct a 
subgroup analysis.
The use of an internet-based sample excludes persons 
without regular access to computers or the internet.   However, 
the ‘digital divide’ has narrowed considerably in the past 
decade. According to a 2010 PewInternet report, 74% of 
Americans aged 18 years and older use the Internet.90 Gender 
  differentials in internet use have disappeared.90 However, age, 
racial, education, and income differentials remain, with older 
persons, those with less income and education, and nonwhite 
Hispanics being less likely to use the internet. In the larger 
study from which the present sample was derived, we noted 
that, compared to the U.S. adult population, the   internet-based 
sample had a slight under-representation of adults with 
income less than $25,000 annually, an over-representation 
of adults with a college education, and over-representation 
of Caucasians.38 Given that the analysis focused on different 
medication-taking behaviors within individuals, we have no 
reason to suspect that these possible sample biases would 
have confounded the observed results.
We controlled for the moderating effect of income 
on the   relationship between patients’ beliefs and their 
  medication-taking behavior. However, we did not have 
information on patients’ out-of-pocket cost associated with 
the prescribed medications or patients’ total cost   burden 
for their medications. Future   studies should examine per-
ceived   medication affordability with respect to different 
  medication-taking behaviors within individual patients. 
Finally, given the relatively small sample size (n = 90) for 
the GEE modeling of persistent versus nonfulfilling   behavior, 
we cannot negate the possibility that our estimates may be 
biased. However, there is no agreement in literature as to what 
represents a sufficient sample size for GEE models.91 Also, 
the number of clusters (ie, subjects with multiple responses) 
in our models far exceeds 30, a common rule of thumb for 
minimum number of clusters required.92
Conclusion
To the best of the authors’ knowledge, the results reported 
herein are the first to empirically demonstrate that patients 
have different beliefs about medications for chronic disease 
to which they persist vs nonpersist and persist vs nonfulfill. 
Patients exhibit different medication-taking behaviors for 
different medications because they weigh the perceived risks 
and benefits for each medication separately.
If adherence is to be improved, then nonfulfillment and non-
persistence needs to be, firstly, recognized and,   secondly, inter-
vened upon. Suboptimal prescription-medication beliefs that 
make patients vulnerable to nonfulfillment and   nonpersistence 
should be addressed relatively early in   therapy. At the point of 
initiating new prescriptions and during   routine follow up visits, 
health care providers can influence patients’ nascent medica-
tion beliefs by eliciting the patient’s   perspective of the per-
ceived benefits and risks of therapy. Addressing the risks and 
benefits of therapy could reinforce positive medication beliefs 
(such as perceived need for medication) and assuage negative 
ones (such as medication concerns). Results from two recent 
meta-analyses support this approach: better physician–patient 
collaboration93 and communication94 was significantly associ-
ated with better adherence.
The results of our study suggest that health care providers 
cannot assume equivalent medication-taking behaviors within 
individual patients. Fulfillment of and persistence with pre-
scribed therapy should be monitored on an individual-medica-
tion basis. Our results also suggest that claims-based predictive 
modeling using historical refill patterns for medications other Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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than an index medication of interest are likely to explain a 
negligible amount of variance in persistence.
The results reported herein support the premise that the 
next generation of adherence interventions must address 
patient beliefs about their medications and conditions and 
not merely focus on reminders, which may only be useful for 
  unintentional nonadherence. This study further demonstrates 
that, within individual patients, salient beliefs vary across 
different medication-taking behaviors. This suggests that 
interventions aimed at improving adherence for patients on 
multiple chronic medications must be tailored to patients’ 
beliefs about specific medications rather than developed 
generically.
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